drugset / Trial / NCT00656747

Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic Bronchitis

NCT00656747

Phase 4 Completed 1372 enrolled Bayer
RandomizedParallel-groupTriple-blindTreatment

Summary

A study to assess the safety and efficacy of moxifloxacin compared to that of amoxicillin-clavulanic acid for the treatment of subjects with acute exacerbation of chronic bronchitis.

Timeline

Start
2008-03
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amoxicillin Other / unclassified 875 mg Oral
Subject Moxifloxacin Small molecule 400 mg Oral
Comparator clavulanic acid Small molecule 125 mg Oral

Indications